Recent developments in the management of interstitial cystitis

Current Opinion in Urology

Volumn 13, Issue 4, 2003, Pages 309-313

  Bouchelouche, Kirsten ^a   Nordling, Joergen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Etiology; Interstitial cystitis; Pelvic pain syndrome; Review; Treatment

Indexed keywords

BCG VACCINE; BIOFLAVONOID; CAPSAICIN; CYSTISTAT; DIMETHYL SULFOXIDE; GABAPENTIN; HEPARIN; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYALURONIC ACID; HYDROXYZINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PENTOSAN POLYSULFATE; RECOMBINANT NERVE GROWTH FACTOR; SILVER NITRATE; SUPLATAST TOSYLATE;

CLINICAL FEATURE; CLINICAL TRIAL; CYSTOSCOPY; HUMAN; INTERSTITIAL CYSTITIS; NEUROMODULATION; PATHOPHYSIOLOGY; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; REVIEW; SELF CARE;

BIOLOGICAL MARKERS; CYSTITIS, INTERSTITIAL; FEMALE; HUMANS; INCIDENCE; PREVALENCE;

EID: 0041866629     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200307000-00007     Document Type: Review

References (37)

1. Gillenwater JY, Wein AJ. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28-29, 1987. J Urol 1988; 140:203-206.
2. Peeker R, Fall M. Toward a precise definition of interstitial cystitis: further evidence of differences in classic and nonulcer disease. J Urol 2002; 167:2470-2472. Today interstitial cystitis is often divided into classic and nonulcer disease. The study demonstrates that the two subtypes of interstitial cystitis represent separate entities. It is suggested that the two subtypes are evaluated separately in clinical studies.
3. Weidner W, Fall M, Bjerklund Johansen TE. Interstitial cystitis and prostatitis. Eur Urol 2002; 42:I-XI.
4. Hanno P. Interstitial cystitis: epidemiology, diagnostic criteria, clinical markers. Rev Urol 2002; 4:S3-S8. Review of epidemiology, diagnostic criteria and clinical markers.
5. Wein AJ, Hanno PM. Targets for therapy of the painful bladder. Urology 2002; 59:68-73. This article reviews the theories of the etiology of interstitial cystitis and the evidence for clinical effectiveness of various treatments.
6. Parsons CL, Dell J, Stanford EJ, et al. The prevalence of interstitial cystitis in gynecologic patients with pelvic pain, as detected by intravesical potassium sensitivity. Am J Obstet Gynecol 2002; 187:1395-1400. Determined the prevalence of interstitial cystitis in a large number of gynecologic patients with pelvic pain compared with controls, as indicated by a positive result on a potassium sensitivity test. Interstitial cystitis may be a common unrecognized cause of pelvic pain in gynecologic patients and deserves greater consideration in the differential diagnosis of pelvic pain.
7. Gregoire M, Liandier F, Naud A, et al. Does the potassium stimulation test predict cystometric, cystoscopic outcome in interstitial cystitis? J Urol 2002; 168:556-557.
8. Erickson DR, Xie SX, Bhavanandan VP, et al. A comparison of multiple urine markers for interstitial cystitis. J Urol 2002; 167:2461-2469. In this study 14 urine markers for interstitial cystitis were tested in 24 h specimens from 36 female patients with interstitial cystitis and 36 age-matched female volunteers. Of all markers studied the antiproliferative factor had the least overlap in the interstitial cystitis and control group, so it may be useful as a diagnostic test. No correlation of marker levels with symptom score was noted in interstitial cystitis patients.
9. Keay SK, Warren JW. Is interstitial cystitis an infectious disease? Int J Antimicrob Agents 2002; 19:480-483. Many interstitial cystitis patients have a small amount of toxic factor (APF) in the urine that may play a role in the pathogenesis of interstitial cystitis. Whether APF is produced by the epithelial cells of interstitial cystitis patients or an unidentified intracellular microorganism is discussed in this paper and remains to be determined.
10. Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology 2001; 57:47-55.
11. El Mansoury M, Boucher W, Sant GR, Theoharides TC. Increased urine histamine and methylhistamine in interstitial cystitis. J Urol 1994; 152:350-353.
12. Bouchelouche K, Kristensen B, Nordling J, et al. Increased urinary leukotriene E4 and eosinophil protein X excretion in patients with interstitial cystitis. J Urol 2001; 166:2121-2125.
13. Moldwin RM, Sant GR. Interstitial cystitis: a pathophysiology and treatment update. Clin Obstet Gynecol 2002; 45:259-272. This article reviews the common therapies used for interstitial cystitis with specific reference to their probable mechanisms of action.
14. Boucher WS, Letourneau R, Huang M, et al. Intravesical sodium hyaluronate inhibits the rat urinary mast cell mediator increase triggered by acute immobilization stress. J Urol 2002; 167:380-384.
15. Sun, Y, Keay S, De Deyne PG, Chai TC. Augmented stretch activated adenosine triphosphate release from bladder uroepithelial cells in patients with interstitial cystitis. J Urol 2001; 166:1951-1956.
16. Sun Y, Chai TC. Effects of dimethyl sulphoxide and heparin on stretch-activated ATP release by bladder urothelial cells from patients with interstitial cystitis. BJU Int 2002; 90:381-385. The study showed that dimethylsulfoxide and heparin attenuated stretch-activated ATP release in cultured interstitial cystitis bladder urothelial cells, suggesting that bladder urothelial purinergic mechanisms are important in bladder sensory function and are altered in interstitial cystitis.
17. Sant GR. Etiology, pathogenesis, and diagnosis of interstitial cystitis. Rev Urol 2002; 4 (Suppl 1):S9-S15. Interstitial cystitis is a bladder syndrome of unknown etiology. The paper discusses etiology, pathogenesis and diagnosis of interstitial cystitis.
18. Lutgendorf SK, Kreder KJ, Rothrock NE, et al. Diurnal cortisol variations and symptoms in patients with interstitial cystitis. J Urol 2002; 167:1338-1343. Implies that regulation of the hypothalamic-pituitary-adrenal axis may be associated with interstitial cystitis symptomatology. The results may have treatment implications for patients with interstitial cystitis who have early morning cortisol deficiencies.
19. Myers DL, Aguilar VC. Gynecologic manifestations of interstitial cystitis. Clin Obstet Gynecol 2002; 45:233-241. There are many gynecologic conditions whose symptoms mimic those of interstitial cystitis. In this paper gynecologic manifestations of interstitial cystitis are described and discussed.
20. Rothrock NE, Lutgendorf SK, Hoffman A, Kreder KJ. Depressive symptoms and quality of life in patients with interstitial cystitis. J Urol 2002; 167:1763-1767.
21. Rothrock NE, Lutgendorf SK, Kreder KJ. Coping strategies in patients with interstitial cystitis: relationships with quality of life and depression. J Urol 2003; 169:233-236.
22. Whitmore K. Complementary and alternative therapies as treatment approaches for interstitial cystitis. Rev Urol 2002; 4:S28-S35.
23. Parsons CL, Forrest J, Nickel JC, et al. Effect of pentosan polysulfate therapy on intravesical potassium sensitivity. Urology 2002; 59:329-333. Intravesical potassium sensitivity test shows abnormal epithelial permeability in most patients with interstitial cystitis and a significant reduction in this permeability after successful pentosan polysulfate (Elmiron) therapy.
24. Larsen S, Thompson SA, Hald T, Barnard RJ, et al. Mast cells in interstitial cystitis. Br J Urol 1982; 54:283-286.
25. Thilagarajah R, Witherow RO, Walker WM. Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. BJU Int 2001; 87:207-212.
26. Bouchelouche K, Horn T, Nordling J, et al. The action of cysteinyl-leukotrienes on intracellular calcium mobilization in human detrusor myocytes. BJU Int 2001; 87:690-696.
27. Bouchelouche K, Nordling J, Hald T, Bouchelouche P. The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis. J Urol 2001; 166:1734-1737.
28. Oberpenning F, van Ophoven A, Hertle L. Interstitial cystitis: an update. Curr Opin Urol 2002; 12:321-332. This review focuses on published literature in 2001.
29. Warren JW, Keay SK. Interstitial cystitis. Curr Opin Urol 2002; 12:69-74. Also a review on reports published in 2001.
30. Glemain P, Riviere C, Lenormand L, et al. Prolonged hydrodistention of the bladder for symptomatic treatment of interstitial cystitis: efficacy at 6 months and 1 year. Eur Urol 2002; 41:79-84.
31. Peters KM. Neuromodulation for the treatment of refractory interstitial cystitis. Rev Urol 2002; 4:S36-S43. The study demonstrates that patients refractory to traditional therapies for interstitial cystitis can respond well to sacral nerve stimulation and maintain improvement in symptoms after permanent implantation of a neurogenerator.
32. Paszkiewicz EJ, Siegel SW, Kirkpatrick C, et al. Sacral nerve stimulation in patients with chronic, intractable pelvic pain [abstract]. Urology 2001; 57 (6 suppl 1):124.
33. Comiter CV. Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study. J Urol 2003; 169:1369-1373. This study demonstrates that sacral neuromodutation may be effective in interstitial cystitis patients who are refractory to other forms of treatment.
34. Chai TC, Zhang C, Warren JW, Keay S. Percutaneous sacral third nerve root neurostimulation improves symptoms and normalizes urinary HB-EGF levels and antiproliferative activity in patients with interstitial cystitis. Urology 2000; 55:643-646.
35. Evans R. Treatment approaches for interstitial cystitis: multimodality therapy. Rev Urol 2002; 4:S16-S20.
36. Wammack R, Remzi M, Seitz C, et al. Efficacy of oral doxepin and piroxicam treatment for interstitial cystitis. Eur Urol 2002; 41:596-600.
37. Leppilahti M, Hellstrom P, Tammela TL. Effect of diagnostic hydrodistension and four intravesical hyaluronic acid instillations on bladder ICAM-1 intensity and association of ICAM-1 intensity with clinical response in patients with interstitial cystitis. Urology 2002; 60:46-51.